Artificial Intelligence (AI)—Integrated Research Facility at Fort Detrick

Artificial intelligence (AI), in its many forms, is applied to infectious disease research at the IRF-Frederick. Primarily focused on medical imaging of preclinical models, state of the art methods are developed, applied to ongoing research and translated to human studies of disease.

H. Clifford Lane, M.D.

Specialty(s): Diagnostic Laboratory Immunology, Infectious Disease, Internal Medicine
Provides direct clinical care to patients at NIH Clinical Center

Education:

M.D., 1976, University of Michigan

H. Clifford Lane, M.D.

Maura Manion, M.D.

Specialty(s): Infectious Disease, Internal Medicine
Provides direct clinical care to patients at NIH Clinical Center

Education:

M.D., Case Western Reserve University, Cleveland, OH

Photo of Maura Manion, M.D.

Irini Sereti, M.D., Ph.D.

Specialty(s): Infectious Disease, Internal Medicine
Provides direct clinical care to patients at NIH Clinical Center

Education:

Ph.D., University of Amsterdam - Netherlands 
M.D., National Kapodistrian University of Athens in Greece
M.H.S., Duke University

Photo of Irini Sereti M.D., M.H.S.

Hyperimmune Intravenous Immunoglobulin Does Not Improve Outcomes for Adults Hospitalized with COVID-19

A clinical trial has found that the combination of remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, is not more effective than remdesivir alone for treating adults hospitalized with the disease. The trial also found that the safety of this experimental treatment may vary depending on whether a person naturally generates SARS-CoV-2-neutralizing antibodies before receiving it. The results of the multinational Phase 3 trial were published today in the journal The Lancet.

Contact

Submit a Media Request

Contact the NIAID News & Science Writing Branch.

301-402-1663
niaidnews@niaid.nih.gov
All Media Contacts

Tratamiento ambulatorio con inmunoglobulina anticoronavirus (Outpatient Treatment with Anti-Coronavirus Immunoglobulin, OTAC)

Un estudio de investigación que prueba un tratamiento contra el COVID-19 en fase de investigación conocido como concentrado de inmunoglobulinas de administración intravenosa hiperinmunitarias (hIVIG) anticoronaviral.

Outpatient Treatment With Anti-Coronavirus Immunoglobulin (OTAC)

A research study testing an experimental COVID-19 treatment called anti-coronavirus hyperimmune intravenous immunoglobulin (hIVIG).

Media Availability—NIH Officials Highlight COVID-19 Vaccine Facts, Unknowns for Healthcare Providers

NIAID Director urges healthcare providers to be able to explain the latest data supporting the safety and efficacy of vaccines for COVID-19.

Contact

Submit a Media Request

Contact the NIAID News & Science Writing Branch.

301-402-1663
niaidnews@niaid.nih.gov
All Media Contacts

Virology—Integrated Research Facility at Fort Detrick

The virology team focuses on gaining a deeper understanding of viral pathogenesis and advancing clinical approaches to assist in managing diseases. The team works with a range of high-consequence viral pathogens.

The team leverages fundamental methodologies, such as: 

Pathology and Histology—Integrated Research Facility at Fort Detrick

The pathology and histology teams work together to conduct morphologic assessments and molecular assays using in-life and postmortem samples attained during research studies that develop and use established animal models of high-consequence emerging human viruses. The clinical pathologic and histopathologic data are interpreted by the pathologists using historical controls, or within-study controls, to generate reports that address specific pathology-associated aims of each study.

Subscribe to Division of Clinical Research (DCR)